Download

Download Full Text (350 KB)

Description

"Development of tumor resistance to chemotherapeutics is related to inherent tumor variations regarding sensitivity to chemotherapeutics and to sub-optimal dosing regimens, including variation in patient pharmacokinetics that result in suboptimal exposure of tumor cells to anti-neoplastic drugs [1, 2]. The rate and extent of drug efficacy depends on the extent of drug exposure at the tumor site and the time above the effective concentration [3]. In vitro models that incorporate these pharmacokinetic and pharmacodynamic (PK/PD) principles to optimize therapeutic response may be considered the method of choice for optimizing dosing schedules before translating data from static assays to animals and clinical trials [4, 5]. The hollow fiber bioreactor was recently used to evaluate pharmacokinetic/pharmacodynamic (PK/PD) effects of gemcitibine in lung and breast cancers and to model HIV treatments [4-6]."

ISBN

978-953-51-0533-6

Publication Date

4-20-2012

Publisher

InTech

City

Rijeka, Croatia

Keywords

tumor resistance, chemotherapeutics, dosing regimens, pharmacokinetics, pharmacodynamics, PK/PD

Disciplines

Medicinal and Pharmaceutical Chemistry | Oncology | Other Chemicals and Drugs | Other Pharmacy and Pharmaceutical Sciences | Pharmaceutical Preparations | Pharmaceutics and Drug Design

Comments

In Ayman M. Noreddin (Ed.), Readings in Advanced Pharmacokinetics - Theory, Methods and Applications. Dr. Noreddin's chapter begins on page 315.

Copyright

The authors

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Anti-Neoplastic Agents

Share

COinS